Bundas24 Bundas24
Resultados de pesquisa
Veja todos os resultados
  • Acessar
    Entrar
    Cadastrar
    Pesquisar
    Night Mode

Pesquisar

Conheça novas pessoas, crie conexões e faça novos amigos

  • Feed de notícias
  • EXPLORAR
  • Páginas
  • Grupos
  • Eventos
  • Blogs
  • Marketplace
  • Funding
  • Offers
  • Jobs
  • Courses
  • Fóruns
  • Publicações
  • Blogs
  • Usuários
  • Páginas
  • Grupos
  • Eventos
  • Kislay Kumar adicionou um novo artigo Outro
    2025-05-19 13:49:52 -
    Advanced Non-Squamous and Squamous NSCLC Market is driven by immunotherapy adoption
    The Advanced Non-Squamous and Squamous NSCLC Market encompasses a broad portfolio of targeted therapies, immune checkpoint inhibitors, and next-generation diagnostics designed to improve patient outcomes in both histological subtypes of non-small cell lung cancer. Products such as PD-1/PD-L1 inhibitors, EGFR tyrosine kinase inhibitors, and novel bispecific antibodies help address treatment...
    0 Comentários 0 Compartilhamentos 271 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
  • Vaibhav Gaikwad adicionou um novo artigo Outro
    2025-04-17 14:48:25 -
    Non-Small Cell Lung Cancer (NSCLC) Market: Transforming Treatment Paradigms
    Non-Small Cell Lung Cancer (NSCLC) Market: Transforming Treatment Paradigms Market Overview The global NSCLC therapeutics market is projected to grow from 18.2billionin2023to18.2billionin2023to32.7 billion by 2030, at a 8.9% CAGR, driven by precision medicine advancements and increasing incidence rates. NSCLC accounts for 85% of all lung cancer cases,...
    0 Comentários 0 Compartilhamentos 425 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
  • Khushbu Coherent adicionou um novo artigo Health
    2025-05-20 09:22:39 -
    EGFR Non-Small Cell Lung Cancer Market Fueled by Targeted Therapies
    The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) market encompasses a range of targeted therapies, companion diagnostics, and supportive care products designed to improve treatment outcomes for patients with EGFR-mutated lung tumors. Key products include first-, second-, and third-generation tyrosine kinase inhibitors (TKIs) that block aberrant EGFR signaling pathways, thereby reducing tumor...
    0 Comentários 0 Compartilhamentos 189 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
© 2025 Bundas24 Portuguese (Brazil)
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Sobre Termos Privacidade Fale conosco Diretório